RANGO Registry

International, multicenter, prospective and observational registry. Evaluation of safety and efficacy of angiolite drug eluting stent in non-selected patients from the clinical daily practice.

Device: angiolite

Number of patients: 654

Follow up: 6, 12 and 24- month

Type of lesion: Non-selected, real world population

Primary endpoint

  • Target Lesion Failure (TLF) at 6, 12 and 24 months

Secondary endpoints

  • Cardiac death at 6, 12 and 24 months
  • Stent thrombosis at 6, 12 and 24 months
  • Myocardial infarction 6, 12 and 24 months
  • Target Lesion Revascularization (TLR) 6, 12 and 24 months

Dr A. Pérez de Prado, Hospital and  University of León (León, SPA)

All Clinicals Trials
ANGIOLITE Trial
ANCHOR Trial